Cytokinetics, Incorporated
CYTK
$36.69
-$0.95-2.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -90.67% | 3,555.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -90.67% | 3,555.94% | |||
| Cost of Revenue | 6.63% | 10.66% | |||
| Gross Profit | -28.11% | 8.85% | |||
| SG&A Expenses | -7.97% | 10.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.80% | 10.41% | |||
| Operating Income | -11.93% | 1.25% | |||
| Income Before Tax | -7.57% | 6.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.57% | 6.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.57% | 6.56% | |||
| EBIT | -11.93% | 1.25% | |||
| EBITDA | -12.20% | 1.25% | |||
| EPS Basic | -7.19% | 6.87% | |||
| Normalized Basic EPS | -7.19% | 6.86% | |||
| EPS Diluted | -7.19% | 6.87% | |||
| Normalized Diluted EPS | -7.19% | 6.86% | |||
| Average Basic Shares Outstanding | 0.36% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.36% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||